Skip to main content
Clinical Trials/IRCT20170809035597N2
IRCT20170809035597N2
Completed
Phase 3

Evaluation of the efficacy and safety of oral pentoxifylline in treatment and recovery of patients with COVID-19 admitted in Rasoul Akram and firoozgar hospitals treated with routine protocols, A randomized controlled clinical trial

Iran University of Medical Sciences0 sites150 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Iran University of Medical Sciences
Enrollment
150
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Admitted patients with COVID\-19
  • Moderate to severe disease
  • Stable patients
  • Patients should not have bleeding disorders
  • Patients do not have a history of heart attack and stroke
  • Patients without history of ocular or cerebral hemorrhage
  • No pregnancy or breastfeeding
  • Patients without history of intolerance to PTX or other xanthines such as caffeine, theophylline and tobromine
  • Patients without gastric ulcers
  • Patient without history of porphyria

Exclusion Criteria

  • Allergy to any of the drugs studied, including pentoxifylline
  • Occurrence of any bleeding during the study (in the stomach, brain, eyes, ...)
  • Drug intolerance or the occurrence of any severe side effects during treatment, such as gastrointestinal intolerance, does not respond to pre\-determined measures of anti\-acids... or the occurrence of skin drug reactions to the received treatment protocol and ...
  • Being pregnant during the study
  • Occurrence of heart attack and stroke during the study
  • Drop in pressure below 10 mm Hg or instability of the patient's vital signs
  • Require intubation during study or hospitalization in the ICU
  • Increase in the severity of COVID\-19 disease during the study so that the need for hospitalization in the ICU or the need to change the treatment protocol
  • The use of a therapeutic drug other than the standard drug in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials